{"id":35,"date":"2023-08-28T21:43:03","date_gmt":"2023-08-28T21:43:03","guid":{"rendered":"https:\/\/onltherapeutics.com\/test\/?page_id=35"},"modified":"2025-10-28T11:32:52","modified_gmt":"2025-10-28T11:32:52","slug":"clinical-trials","status":"publish","type":"page","link":"https:\/\/onltherapeutics.com\/test\/clinical-trials\/","title":{"rendered":"Clinical Trials"},"content":{"rendered":"\n
<\/div><\/span>
\n

Clinical Trials<\/p>\n<\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n

ONL is leveraging its innovative neuroprotection platform technology to develop new treatments for multiple, vision-threatening retinal diseases<\/h3>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n

ONL\u2019s lead therapeutic candidate, xelafaslatide (formerly ONL1204), is a first-in-class small peptide that effectively inhibits the Fas receptor, thus blocking the activation of the Fas pathway and the related immune signaling which results in the death of key retinal cells and loss of vision.<\/p>\n\n\n\n

Xelafaslatide is designated an investigational drug and is not approved for commercial use. As such, the information on this page was created for scientific exchange with Healthcare Professionals only.<\/p>\n\n\n\n

Across all completed clinical studies to date, xelafaslatide has been found to be generally safe and well tolerated, under the planned oversight and guidance of safety review committees.<\/p>\n\n\n\n

Learn more about our clinical trials below:<\/strong><\/p>\n\n\n\n

<\/div>\n\n\n\n
\n
\n
\n
\n
\"\"<\/figure>\n\n\n\n
<\/div>\n<\/div>\n\n\n\n
\n

Dry AMD\/GA<\/p>\n<\/div>\n<\/div>\n\n\n\n

A Phase 2 Multicenter, Randomized, Double-masked, Sham-controlled, Reference-arm Study to Evaluate Efficacy and Safety of ONL1204 (Xelafaslatide) in Patients With Geographic Atrophy (GA) Associated With Age-related Macular Degeneration (AMD)<\/p>\n\n\n\n

The purpose of this study is to collect efficacy and safety information across 3 experimental arms, including 2 dose levels of ONL1204 and 2 treatment frequencies (once every 12 weeks or 24 weeks) in patients with GA associated with AMD.<\/p>\n\n\n\n

<\/div>\n\n\n\n
<\/div>\n<\/div>\n\n\n\n
\n
<\/div>\n\n\n\n

\"\" ACTIVE<\/p>\n\n\n\n

NCT06659445<\/p>\n\n\n\n

Phase 2<\/p>\n\n\n\n

Intravitreal (IVT) Injection ONL1204:<\/p>\n\n\n\n

\n
\n